EAGAN, Minn.--(BUSINESS WIRE)--Peter J. Maimonis, Ph.D. has joined Biothera as Vice President of Biomarker Development and will lead the development and commercialization of assays for the company’s Phase 3 cancer immunotherapy, Imprime PGG®.
Dr. Maimonis previously held several senior positions with various pharmaceutical and diagnostic companies, including Senior Director – Cancer Cell Biology, On-Q-ity; Vice President – Biology R&D, Decision Biomarkers; and Associate Director for Oncology Research, Bayer Health Care.
“For the past quarter century Dr. Maimonis has focused on the discovery and development of oncology biomarkers, companion diagnostics and assays,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “His expertise is a perfect fit for Biothera as we advance the science of the predictive biomarker for Imprime PGG.”
Dr. Maimonis received his doctorate in tumor immunology from Brown University and completed his post-doctoral training at Dana Farber Cancer Institute. He was a Research Fellow at Harvard Medical School.
Biothera is a U.S. biotechnology company that is developing Imprime PGG, a novel cancer immunomodulatory drug. Innate immune cells are the most abundant immune cells in the body and are normally responsible for pathogen killing, but not anti-tumor activity. However, Imprime PGG has been shown to bind to neutrophils and monocytes and redirect their killing ability to reduce tumor growth and enhance long-term survival. This targeted mechanism is synergistic with multiple anti-tumor monoclonal antibodies, providing the potential to improve patient outcomes in a wide range of cancer indications. Imprime PGG has demonstrated marked improvements in overall response rates in multiple clinical trials for colorectal cancer, KRAS-mutant colorectal cancer and chronic lymphocytic leukemia. Imprime PGG is currently in a Phase 3 clinical trial for advanced colorectal cancer and a Phase 2 NSCLC study with bevacizumab (Avastin®).
For more information, visit our website at www.biothera.com/pharma.